Since 2010, we’ve taken a radically different approach to fusion – building businesses that solve problems now while advancing toward fusion energy. As we mark our 15th anniversary, we're celebrating the milestones that transformed us from a startup with a bold idea into today's fusion company.
We've navigated uncharted regulatory territory, achieved world records, and gained international recognition as a fusion technology leader. The result: we're making money from fusion today. Our fusion neutrons are strengthening national security, building the foundation for abundant clean energy, and soon will produce medical isotopes that help diagnose and treat disease.
Fifteen years in, these milestones prove that the fastest path to fusion energy runs through SHINE.
SHINE ON!!
- 2010: We launched today’s fusion company. SHINE officially incorporated in Janesville, Wisconsin.
- 2011: Government funding backed our fusion approach. We established our longstanding partnership with the Department of Energy for fusion-based medical isotope production.
- 2015: Independent experts validated our process. Argonne National Lab independently confirmed our isotope production process meets pharmaceutical standards.
- 2016: NRC approved our fusion facility designs. We received the first-ever NRC construction permit for a fusion-based medical isotope facility, creating an entirely new category.
- 2018: We closed our first institutional investment round. Private funding validated our commercial potential as we transitioned from being government-funded to investor-backed.
- 2019: Construction began on Chrysalis. It will be the world's largest medical isotope production facility, capable of meeting nearly half of global demand for Mo-99 and improving access to other isotopes.
- 2019: Our fusion technology set a world record. We achieved 46 trillion neutrons per second, beating the previous world record by 25% for the strongest sustained nuclear fusion reaction in a steady-state system.
- 2020: First cancer-fighting isotopes (Lu-177) sold and delivered. We transitioned from research and development to commercial operations.
- 2021: Acquiring Phoenix consolidated our fusion advantage. Phoenix, which started in 2005, was our founder’s first company.
- 2023: Landmark NRC approval achieved. NRC concluded we met all technical requirements for an operating license, marking the first such achievement in decades for any company.
- 2023: Fusion became visible through Cherenkov radiation. We captured the first-ever image of Cherenkov radiation from a commercial fusion device, demonstrating reactor-level neutron production.
- 2023: FLARE began testing mission-critical components. With FLARE, our new radiation effects testing service, we began providing fusion neutron testing services for defense and aerospace industries.
- 2024: First cancer-fighting Ilumira (Lu-177) doses delivered from Cassiopeia. The United States’ first commercial-scale n.c.a. Lu-177 facility became operational and our Ilumira (Lu-177) began treating cancer patients.
- 2024: FDA filing completed for Ilumira. Submitting our Drug Master File for Ilumira established our pathway for expanded distribution, so more patients with cancer could receive treatments.
- 2025: UKAEA chose our fusion technology. The UK Atomic Energy Authority selected us to provide the fusion neutron source for their global fusion research program, LIBRTI.
This anniversary year gives us another milestone to celebrate:
2025: Lantheus SPECT acquisition announced. We plan to expand patient access to critical diagnostics through our Lantheus SPECT acquisition, adding technetium-99m generators and other essential medical isotopes to our portfolio.
